Cargando…
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940562/ https://www.ncbi.nlm.nih.gov/pubmed/35318561 http://dx.doi.org/10.1007/s10072-022-05961-9 |
| _version_ | 1784672951972397056 |
|---|---|
| author | Mariottini, Alice Repice, Anna Maria Barilaro, Alessandro Massacesi, Luca |
| author_facet | Mariottini, Alice Repice, Anna Maria Barilaro, Alessandro Massacesi, Luca |
| author_sort | Mariottini, Alice |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8940562 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89405622022-03-23 Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance Mariottini, Alice Repice, Anna Maria Barilaro, Alessandro Massacesi, Luca Neurol Sci Covid-19 Springer International Publishing 2022-03-23 2022 /pmc/articles/PMC8940562/ /pubmed/35318561 http://dx.doi.org/10.1007/s10072-022-05961-9 Text en © Fondazione Società Italiana di Neurologia 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Covid-19 Mariottini, Alice Repice, Anna Maria Barilaro, Alessandro Massacesi, Luca Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance |
| title | Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance |
| title_full | Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance |
| title_fullStr | Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance |
| title_full_unstemmed | Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance |
| title_short | Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance |
| title_sort | anti-sars-cov2 vaccination at the time of the covid-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance |
| topic | Covid-19 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940562/ https://www.ncbi.nlm.nih.gov/pubmed/35318561 http://dx.doi.org/10.1007/s10072-022-05961-9 |
| work_keys_str_mv | AT mariottinialice antisarscov2vaccinationatthetimeofthecovid19pandemicsuspectedadverseeventsreportingisthemilestoneofpostmarketingsurveillance AT repiceannamaria antisarscov2vaccinationatthetimeofthecovid19pandemicsuspectedadverseeventsreportingisthemilestoneofpostmarketingsurveillance AT barilaroalessandro antisarscov2vaccinationatthetimeofthecovid19pandemicsuspectedadverseeventsreportingisthemilestoneofpostmarketingsurveillance AT massacesiluca antisarscov2vaccinationatthetimeofthecovid19pandemicsuspectedadverseeventsreportingisthemilestoneofpostmarketingsurveillance |